Desde el departamento de Información Médica de Boehringer Ingelheim te ofrecemos video resúmenes de nuestros estudios que te permitirán mantenerte actualizado de forma ágil y rápida.
VIDEO 1
Ensayo clínico EMPEROR-Preserved
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi: 10.1056/NEJMoa2022190.
- Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21(10):1270-1278. doi: 10.1002/ejhf.1536.
- Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019;21(10):1279-1287. doi: 10.1002/ejhf.1596.
- Anker SD, Butler J, Filippatos G, et al. Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail. 2020;22(12):2383-2392. doi: 10.1002/ejhf.2064.
- Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; doi: 10.1056/NEJMoa2107038.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: 10.1056/NEJMoa1504720.
- Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin, in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME Trial. Eur Heart J. 2016;37(19):1526-1534 and Supplementary Material. doi: 10.1093/eurheartj/ehv728.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357. doi: 10.1056/NEJMoa1812389.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744.
- Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J. 2018;39:363–370. doi: 10.1093/eurheartj/ehx511.
- Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018;138: 458–468. doi: 10.1161/CIRCULATIONAHA.118.034222.
- Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J. 2018;206:11-23. doi: 10.1016/j.ahj.2018.08.016.
VIDEO 2
Ensayo clínico EMPEROR-Reduced
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi: 10.1056/NEJMoa1504720.
- Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin, in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME Trial. Eur Heart J. 2016;37(19):1526-34 and Supplementary Material. doi: 10.1093/eurheartj/ehv728.
- Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. doi: 10.1056/NEJMoa1812389.
- Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–2306. doi: 10.1056/NEJMoa1811744.
- Radholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation 2018;138: 458–468. doi: 10.1161/CIRCULATIONAHA.118.034222.
- Fitchett D, Butler J, van de Borne P, et al. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. Eur Heart J 2018;39:363–370. doi: 10.1093/eurheartj/ehx511.
- Cannon CP, McGuire DK, Pratley R, et al. Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). doi: 10.1016/j.ahj.2018.08.016.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413-1424. doi: 10.1056/NEJMoa2022190.
- Packer M, Butler J, Filippatos GS, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. Eur J Heart Fail. 2019;21(10):1270-1278. doi: 10.1002/ejhf.1536.
- Anker SD, Butler J, Filippatos GS, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019;21(10):1279-1287. doi: 10.1002/ejhf.1596.
- ClinicalTrials.gov. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) [Internet]. Bethesda (MD): National Library of Medicine (US); [May 2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT03057977. NLM Identifier: NCT03057977.
- Packer M and Zannad F. EMPEROR-Reduced Trial. Effect of empagliflozin on cardiovascular and renal events in heart failure with a reduced ejection fraction. Oral presentation at: European Society of Cardiology (ESC) Congress; 29 Aug 2020.
- Data on File. Boehringer Ingelheim Pharmaceuticals, Inc. Ingelheim, Germany. 2020
PC-ES-110933